arrow
L

Lydia Montes

service d’hématologie, chu amiens
H指数:11
被引数:414

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05)

BENEFIT研究(IFM2020-05)中高危初诊非移植候选多发性骨髓瘤的MRD纵向评估

2026-10-050
OAAI
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia

POD24是沃尔德斯特伦巨球蛋白血症患者预后的新型决定因素。

2026-01-090
OAAI
Waldenström’s macroglobulinemia: the LYSA pragmatic guidelines

华氏巨球蛋白血症:LYSA实用指南

2025-11-280
PRE
High-risk genomic consensus validation in newly diagnosed multiple myeloma patients using next-generation sequencing

使用下一代测序对 newly diagnosed multiple myeloma 患者进行高风险基因组共识验证

Blood
IF23.1
2025-09-260
PRE
Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas

ASCT与CAR T细胞疗法串联联合治疗高度难治性CNS淋巴瘤

2025-08-310
OAAI
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study

抗CD38单克隆抗体在初诊多发性骨髓瘤患者一线治疗中的影响:来自EMMY研究的真实世界结果

2025-07-240
PRE
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program

Teclesitamab在复发难治性多发性骨髓瘤中的应用:一项来自法国早期准入项目的多中心真实世界研究

2024-11-211
OA
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024-06-038
OAAI
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
2023-10-2611
OAAI
SARS-CoV-2 Infection in Patients With Waldenstrom's Macroglobulinemia: A Multicenter International Cohort Study
2023-06-011
OAAI
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
2023-04-209
OAAI
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
2020-06-0551
OAAI